ArticlePharmaceuticals (Basel, Switzerland)2022
Application of Optical Methods for Determination of Concentration of Doxorubicin in Blood and Plasma.
Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 39 citations in OpenAlex.
- Doxorubicin-Loaded Cerium Oxide Nanoparticles Suppress Cell Proliferation, Migration and Invasion of Triple-Negative Breast Cancer Cells.ACS omega · 2026Article
- The Synthesis and Anticancer Activity of the Trastuzumab-Doxorubicin Antibody-Drug Conjugate Using Strain-Promoted Alkyne-Azide Coupling.ACS omega · 2026Article
- Bio-reductive Co(iii)-doxorubicin complex for cancer cell-selective delivery of doxorubicin and potent anticancer activity.RSC medicinal chemistry · 2025Article
- Enhanced therapeutic efficacy of platinum-doxorubicin nanoparticles on colon and breast cancer cell lines.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Temporally programmed STING nanoadjuvant delivery unlocks synergistic chemotherapy-induced antitumor immunity.Science advances · 2025Article
- Doxorubicin detection in plasma and blood using a luminescence turn-off nanosensor based on alloyed CdZnSeS/ZnS quantum dots.Mikrochimica acta · 2025Article
- Utilizing Copper Nanoclusters as a Fluorescent Probe for Quantitative Monitoring of Doxorubicin Anticancer Drug.Journal of fluorescence · 2025Article
- Development of advanced drug-loaded graphene quantum dots with improved photoluminescence properties for enhanced targeted therapy and nano-imaging technologies.RSC advances · 2025Article
- Inhibition of cytochrome P450 epoxygenase promotes endothelium-to-mesenchymal transition and exacerbates doxorubicin-induced cardiovascular toxicity.Molecular biology reports · 2024Article
- Article
- Article
- Near-Field Communication Tag for Colorimetric Glutathione Determination with a Paper-Based Microfluidic Device.Biosensors · 2023Article
- A Lateral Flow Device for Point-of-Care Detection of Doxorubicin.Biosensors · 2022Article
- Novel Oncologic Strategies in Osteosarcoma Management: Maximizing Impact, Minimizing Harm.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of presented research is to develop a simple and quick method of spectrophotometric detection for the determination of doxorubicin hydrochloride in blood and plasma. Anthracycline antibiotics are among the most effective antineoplastic agents. However, despite their high efficacy in the treatment of various types of cancer, their administration is limited primarily because they exhibit myocardial toxicity. This may be a limiting factor in the dosage of medications; nevertheless, drugs exhibiting this mechanism of action constitute a very important group of chemotherapeutics. One of the more widely studied antibiotics from the anthracycline group is doxorubicin. It exhibits the highest antineoplastic activity from among a number of derivative compounds. Because of the adverse effects of doxorubicin, especially cardiotoxicity, it is important to maintain control of its concentration in body fluids. The method in the study consists of extraction doxorubicin from the plasma or blood and measurements of the absorbance of light in the visible light range in a DOX solution with respect to a reference sample. The research used blood and plasma samples spiked with doxorubicin to give concentrations in the range of 0.2-10 µg/mL. Obtained LODs were 1.6 µg/mL and 1.2 µg/mL, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.